BioNTech (NASDAQ:BNTX) Earns Buy Rating from Analysts at Berenberg Bank

Berenberg Bank assumed coverage on shares of BioNTech (NASDAQ:BNTX) in a research note issued to investors on Tuesday morning, Marketbeat reports. The firm issued a buy rating and a $130.00 price objective on the stock.

A number of other research analysts also recently commented on the company. UBS Group increased their price target on BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a report on Wednesday, September 18th. Jefferies Financial Group raised shares of BioNTech from a “hold” rating to a “buy” rating and raised their price target for the stock from $96.00 to $150.00 in a research report on Tuesday, September 17th. TD Cowen reduced their price objective on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a research note on Tuesday, November 5th. Hsbc Global Res raised shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 2nd. Finally, Evercore ISI upgraded BioNTech from an “in-line” rating to an “outperform” rating and lifted their price target for the stock from $110.00 to $125.00 in a research note on Tuesday. Four investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, BioNTech has a consensus rating of “Moderate Buy” and an average price target of $138.79.

BioNTech Stock Performance

BioNTech stock opened at $113.13 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. BioNTech has a one year low of $76.53 and a one year high of $131.49. The stock’s 50 day moving average price is $113.60 and its 200 day moving average price is $97.70. The firm has a market capitalization of $27.12 billion, a PE ratio of -53.87 and a beta of 0.26.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $2.07. The firm had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm’s quarterly revenue was up 38.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.73 EPS. As a group, sell-side analysts expect that BioNTech will post -3.68 EPS for the current fiscal year.

Institutional Investors Weigh In On BioNTech

Several large investors have recently made changes to their positions in BNTX. Janney Montgomery Scott LLC bought a new position in BioNTech in the 1st quarter worth approximately $314,000. ProShare Advisors LLC increased its holdings in shares of BioNTech by 10.4% during the first quarter. ProShare Advisors LLC now owns 6,785 shares of the company’s stock valued at $626,000 after purchasing an additional 637 shares during the period. Covestor Ltd raised its stake in shares of BioNTech by 47.2% during the first quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after purchasing an additional 133 shares in the last quarter. CANADA LIFE ASSURANCE Co lifted its holdings in BioNTech by 79.6% in the first quarter. CANADA LIFE ASSURANCE Co now owns 3,426 shares of the company’s stock worth $316,000 after purchasing an additional 1,518 shares during the period. Finally, Crewe Advisors LLC bought a new position in BioNTech in the 1st quarter valued at about $75,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.